First Turn Management LLC raised its position in Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 17.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 474,839 shares of the company’s stock after buying an additional 72,028 shares during the period. Apogee Therapeutics comprises about 4.1% of First Turn Management LLC’s portfolio, making the stock its 9th largest holding. First Turn Management LLC’s holdings in Apogee Therapeutics were worth $35,841,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of APGE. Wellington Management Group LLP boosted its holdings in Apogee Therapeutics by 24.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock worth $187,673,000 after buying an additional 917,991 shares during the last quarter. UBS Group AG boosted its holdings in Apogee Therapeutics by 646.1% in the 3rd quarter. UBS Group AG now owns 799,465 shares of the company’s stock worth $31,763,000 after buying an additional 692,308 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after buying an additional 612,193 shares during the last quarter. Remedium Capital Partners LLC acquired a new stake in Apogee Therapeutics in the 4th quarter worth about $44,050,000. Finally, Jennison Associates LLC acquired a new stake in Apogee Therapeutics in the 4th quarter worth about $43,675,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $78.71, for a total transaction of $432,905.00. Following the transaction, the insider owned 205,648 shares of the company’s stock, valued at approximately $16,186,554.08. The trade was a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $82.58, for a total value of $1,651,600.00. Following the transaction, the chief executive officer directly owned 1,132,987 shares in the company, valued at $93,562,066.46. This trade represents a 1.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 76,500 shares of company stock worth $6,323,295 in the last three months. 24.30% of the stock is currently owned by corporate insiders.
Apogee Therapeutics Stock Performance
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.01. As a group, sell-side analysts forecast that Apogee Therapeutics Inc. will post -4.45 EPS for the current year.
Analyst Ratings Changes
Several research firms recently issued reports on APGE. Truist Financial lowered their price objective on Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating on the stock in a report on Wednesday, May 27th. Rothschild & Co Redburn began coverage on Apogee Therapeutics in a report on Friday, May 1st. They issued a “buy” rating and a $140.00 price objective on the stock. Guggenheim lifted their price objective on Apogee Therapeutics from $130.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Monday, April 20th. Finally, Citigroup lifted their price objective on Apogee Therapeutics from $95.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Apogee Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $114.56.
Check Out Our Latest Report on Apogee Therapeutics
Apogee Therapeutics Profile
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Stories
- Five stocks we like better than Apogee Therapeutics
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report).
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
